Bacillus Coagulans Patent Landscape
Identifiers
Hazards
Which organizations and claims shape current development around bacillus coagulans?
Key organizations include Qingdao Vland Biotech (blood glucose reduction), Sami Labs (cholesterol reduction, beverage viability), Ganeden Biotech (physical performance), and My Health Int/My Research (functional GI disorders). Claims focus on specific deposited strains (e.g., VHProbi C08, MTCC 5856, GBI-30) and their metabolic outputs, such as α-glucosidase inhibition and polyamine production. These organizations are advancing strain-specific intellectual property, but patent filings do not indicate product adoption or market presence.
How is Bacillus coagulans innovation changing in Food & Beverage?
Monthly patent filings by domain
Which technical problems do recent patents address with bacillus coagulans?
Recent patents address strain-specific efficacy and survival in challenging product matrices. Technical problems include improving digestive health (lactose intolerance, protein digestion), managing metabolic conditions (blood glucose, uric acid, cholesterol), and enhancing stress resistance and anti-aging effects. Formulation challenges focus on maintaining viability in room-temperature acidic beverages, during tea brewing, and in fresh produce, as well as improving stability via microencapsulation. These patents claim solutions through novel strain selection and protective delivery systems, but they do not prove commercial adoption.
How do recent patents change the role or application of bacillus coagulans?
Bacillus coagulans is shifting from a general probiotic to a targeted therapeutic and functional ingredient. Patents claim roles in blood glucose reduction, uric acid lowering, cholesterol assimilation, anti-aging, and physical performance enhancement. The ingredient is also used as a fermentation inoculant to degrade anti-nutritional factors in feed, and as a producer of bioactive metabolites like indole derivatives and polyamines. This diversification suggests a move toward clinical and metabolic applications, but these are claimed approaches, not established product functions.
How is Bacillus coagulans used in Food & Beverage patents?
Which Food & Beverage product categories feature Bacillus coagulans in recent patents?
Which product categories and formulation strategies emerge in recent work on bacillus coagulans?
Emerging product categories include functional beverages (room-temperature acidic drinks, brewed teas), probiotic-fortified fresh produce, sports nutrition compositions, and pharmaceutical formulations for functional GI disorders. Formulation strategies emphasize spore stability, microencapsulation with prebiotic wall materials (inulin, xanthan gum), and combination with other probiotic strains (e.g., B. subtilis) or herbal extracts. These strategies aim to protect viability in harsh environments and enhance efficacy through synergy, but they are patent claims, not market evidence.
Where is the evidence-backed white space for further development of bacillus coagulans?
Evidence-backed white space exists in combining Bacillus coagulans with other Bacillus species for functional GI disorders, as shown in patents pairing it with B. subtilis. Another area is using inactivated or dead cells for benefits like physical performance, which could enable shelf-stable products without viability concerns. Additionally, colonization of fresh produce tissue by spore-forming strains offers a novel delivery route. These are claimed approaches, and further development would require validation of efficacy and consumer acceptance.